S&P 500   3,370.29 (-0.29%)
DOW   29,232.19 (-0.56%)
QQQ   234.73 (+0.04%)
AAPL   319.00 (-1.83%)
FB   217.80 (+1.69%)
MSFT   187.23 (+1.01%)
GOOGL   1,519.44 (+0.05%)
AMZN   2,155.67 (+0.97%)
CGC   21.94 (-0.86%)
NVDA   296.57 (+2.34%)
BABA   220.52 (+0.41%)
MU   57.75 (-1.28%)
GE   12.75 (-0.62%)
TSLA   858.40 (+7.30%)
AMD   56.89 (+2.86%)
T   38.26 (+0.03%)
ACB   1.64 (+3.80%)
F   8.06 (-0.49%)
NFLX   387.78 (+1.94%)
PRI   135.62 (-0.89%)
BAC   34.27 (-1.66%)
DIS   139.14 (-0.29%)
GILD   67.01 (-0.81%)
S&P 500   3,370.29 (-0.29%)
DOW   29,232.19 (-0.56%)
QQQ   234.73 (+0.04%)
AAPL   319.00 (-1.83%)
FB   217.80 (+1.69%)
MSFT   187.23 (+1.01%)
GOOGL   1,519.44 (+0.05%)
AMZN   2,155.67 (+0.97%)
CGC   21.94 (-0.86%)
NVDA   296.57 (+2.34%)
BABA   220.52 (+0.41%)
MU   57.75 (-1.28%)
GE   12.75 (-0.62%)
TSLA   858.40 (+7.30%)
AMD   56.89 (+2.86%)
T   38.26 (+0.03%)
ACB   1.64 (+3.80%)
F   8.06 (-0.49%)
NFLX   387.78 (+1.94%)
PRI   135.62 (-0.89%)
BAC   34.27 (-1.66%)
DIS   139.14 (-0.29%)
GILD   67.01 (-0.81%)
S&P 500   3,370.29 (-0.29%)
DOW   29,232.19 (-0.56%)
QQQ   234.73 (+0.04%)
AAPL   319.00 (-1.83%)
FB   217.80 (+1.69%)
MSFT   187.23 (+1.01%)
GOOGL   1,519.44 (+0.05%)
AMZN   2,155.67 (+0.97%)
CGC   21.94 (-0.86%)
NVDA   296.57 (+2.34%)
BABA   220.52 (+0.41%)
MU   57.75 (-1.28%)
GE   12.75 (-0.62%)
TSLA   858.40 (+7.30%)
AMD   56.89 (+2.86%)
T   38.26 (+0.03%)
ACB   1.64 (+3.80%)
F   8.06 (-0.49%)
NFLX   387.78 (+1.94%)
PRI   135.62 (-0.89%)
BAC   34.27 (-1.66%)
DIS   139.14 (-0.29%)
GILD   67.01 (-0.81%)
S&P 500   3,370.29 (-0.29%)
DOW   29,232.19 (-0.56%)
QQQ   234.73 (+0.04%)
AAPL   319.00 (-1.83%)
FB   217.80 (+1.69%)
MSFT   187.23 (+1.01%)
GOOGL   1,519.44 (+0.05%)
AMZN   2,155.67 (+0.97%)
CGC   21.94 (-0.86%)
NVDA   296.57 (+2.34%)
BABA   220.52 (+0.41%)
MU   57.75 (-1.28%)
GE   12.75 (-0.62%)
TSLA   858.40 (+7.30%)
AMD   56.89 (+2.86%)
T   38.26 (+0.03%)
ACB   1.64 (+3.80%)
F   8.06 (-0.49%)
NFLX   387.78 (+1.94%)
PRI   135.62 (-0.89%)
BAC   34.27 (-1.66%)
DIS   139.14 (-0.29%)
GILD   67.01 (-0.81%)
Log in

NASDAQ:OXFD - Oxford Immunotec Global Stock Price, Forecast & News

$14.93
+0.27 (+1.84 %)
(As of 02/18/2020 04:00 PM ET)
Today's Range
$14.60
Now: $14.93
$14.98
50-Day Range
$14.46
MA: $15.90
$17.05
52-Week Range
$12.49
Now: $14.93
$18.60
Volume87,300 shs
Average Volume112,262 shs
Market Capitalization$394.85 million
P/E Ratio2.86
Dividend YieldN/A
Beta0.42
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. Read More…

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OXFD
CUSIPN/A
Phone44-0-12-3544-2780

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$59.75 million
Cash Flow$0.68 per share
Book Value$8.12 per share

Profitability

Net Income$120.78 million

Miscellaneous

Employees215
Market Cap$394.85 million
Next Earnings Date3/9/2020 (Estimated)
OptionableNot Optionable

Receive OXFD News and Ratings via Email

Sign-up to receive the latest news and ratings for OXFD and its competitors with MarketBeat's FREE daily newsletter.


Oxford Immunotec Global (NASDAQ:OXFD) Frequently Asked Questions

What is Oxford Immunotec Global's stock symbol?

Oxford Immunotec Global trades on the NASDAQ under the ticker symbol "OXFD."

How were Oxford Immunotec Global's earnings last quarter?

Oxford Immunotec Global PLC (NASDAQ:OXFD) posted its earnings results on Tuesday, November, 5th. The company reported $0.04 earnings per share for the quarter, topping analysts' consensus estimates of ($0.05) by $0.09. The company earned $21.20 million during the quarter, compared to analyst estimates of $20.23 million. Oxford Immunotec Global had a return on equity of 15.77% and a net margin of 199.21%. Oxford Immunotec Global's revenue was up 31.7% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.13) earnings per share. View Oxford Immunotec Global's Earnings History.

When is Oxford Immunotec Global's next earnings date?

Oxford Immunotec Global is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Oxford Immunotec Global.

What price target have analysts set for OXFD?

2 Wall Street analysts have issued 12 month price objectives for Oxford Immunotec Global's shares. Their forecasts range from $20.00 to $20.00. On average, they expect Oxford Immunotec Global's share price to reach $20.00 in the next twelve months. This suggests a possible upside of 34.0% from the stock's current price. View Analyst Price Targets for Oxford Immunotec Global.

What is the consensus analysts' recommendation for Oxford Immunotec Global?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oxford Immunotec Global in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oxford Immunotec Global.

Has Oxford Immunotec Global been receiving favorable news coverage?

News stories about OXFD stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Oxford Immunotec Global earned a news impact score of 0.8 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Oxford Immunotec Global.

Are investors shorting Oxford Immunotec Global?

Oxford Immunotec Global saw a decline in short interest in the month of January. As of January 31st, there was short interest totalling 386,200 shares, a decline of 6.0% from the January 15th total of 411,000 shares. Based on an average daily volume of 116,200 shares, the short-interest ratio is currently 3.3 days. Approximately 1.5% of the company's shares are short sold. View Oxford Immunotec Global's Current Options Chain.

Who are some of Oxford Immunotec Global's key competitors?

What other stocks do shareholders of Oxford Immunotec Global own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oxford Immunotec Global investors own include AbbVie (ABBV), Immunomedics (IMMU), Intel (INTC), Sangamo Therapeutics (SGMO), Gold Resource (GORO), Adaptimmune Therapeutics (ADAP), Akorn (AKRX), Gilead Sciences (GILD), Halozyme Therapeutics (HALO) and Centurylink (CTL).

Who are Oxford Immunotec Global's key executives?

Oxford Immunotec Global's management team includes the folowing people:
  • Dr. Peter Wrighton-Smith, CEO & Exec. Director (Age 45)
  • Mr. Jeff R. Schroeder, Pres, Strategic Accounts (Age 58)
  • Mr. Matthew T.E. McLaughlin, Chief Financial Officer (Age 42)
  • Mr. Stefan C. Linn, Chief Operating Officer (Age 54)
  • Ms. Karen C. Koski, VP of Strategy & Investor Relations

Who are Oxford Immunotec Global's major shareholders?

Oxford Immunotec Global's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Alyeska Investment Group L.P. (4.91%), Penn Capital Management Co. Inc. (2.91%), Senvest Management LLC (2.64%), Renaissance Technologies LLC (1.57%), Man Group plc (1.37%) and New York State Common Retirement Fund (1.27%). Company insiders that own Oxford Immunotec Global stock include Elizabeth M Keiley, Peter Wrighton-Smith and Richard A Sandberg. View Institutional Ownership Trends for Oxford Immunotec Global.

Which major investors are selling Oxford Immunotec Global stock?

OXFD stock was sold by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P., Man Group plc, Oxford Asset Management LLP, Renaissance Technologies LLC, Oppenheimer & Co. Inc., Goldman Sachs Group Inc. and Connor Clark & Lunn Investment Management Ltd.. Company insiders that have sold Oxford Immunotec Global company stock in the last year include Elizabeth M Keiley, Peter Wrighton-Smith and Richard A Sandberg. View Insider Buying and Selling for Oxford Immunotec Global.

Which major investors are buying Oxford Immunotec Global stock?

OXFD stock was purchased by a variety of institutional investors in the last quarter, including Penn Capital Management Co. Inc., New York State Common Retirement Fund, Knights of Columbus Asset Advisors LLC, Acadian Asset Management LLC, Senvest Management LLC, Alliancebernstein L.P., California Public Employees Retirement System and Russell Investments Group Ltd.. View Insider Buying and Selling for Oxford Immunotec Global.

How do I buy shares of Oxford Immunotec Global?

Shares of OXFD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Oxford Immunotec Global's stock price today?

One share of OXFD stock can currently be purchased for approximately $14.93.

How big of a company is Oxford Immunotec Global?

Oxford Immunotec Global has a market capitalization of $394.85 million and generates $59.75 million in revenue each year. The company earns $120.78 million in net income (profit) each year or $0.51 on an earnings per share basis. Oxford Immunotec Global employs 215 workers across the globe.View Additional Information About Oxford Immunotec Global.

What is Oxford Immunotec Global's official website?

The official website for Oxford Immunotec Global is http://www.oxfordimmunotec.com/.

How can I contact Oxford Immunotec Global?

Oxford Immunotec Global's mailing address is 94C INNOVATION DRIVE MILTON PARK, ABINGDON X0, OX14 4RZ. The company can be reached via phone at 44-0-12-3544-2780 or via email at [email protected]


MarketBeat Community Rating for Oxford Immunotec Global (NASDAQ OXFD)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  251 (Vote Outperform)
Underperform Votes:  256 (Vote Underperform)
Total Votes:  507
MarketBeat's community ratings are surveys of what our community members think about Oxford Immunotec Global and other stocks. Vote "Outperform" if you believe OXFD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OXFD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel